The year 2022 marks 20 years of major advances in the diagnosis and management of cystic fibrosis in France and around the world:
These measures have made it possible to improve the prognosis of this disease, allowing early diagnosis and multidisciplinary management organized within the CRCMs from the first weeks of life thanks to neonatal screening. The benefits for patients have been observed at all levels of care, with a favorable cost-benefit ratio:
Despite these important advances, many patients are still missing out on innovative treatments. In addition, there are currently no curative treatments for patients with cystic fibrosis. Thus, further efforts are needed to continue to combat this disease.
The “Virades de l’espoir”, created in 1985, help raise awareness of the fight against cystic fibrosis and raise funds to improve the lives of patients with the disease, most notably by funding research into the development of new treatments.
Alzheimer’s disease is a major global healthcare challenge. The number of people living with Alzheimer’s disease or other forms of dementia is currently estimated at over 55 million worldwide, and this number is expected to reach 78 million by 2030. The prevalence of dementia is estimated at around 10 million across all European countries, and is expected to almost double by 2050. In France, 2.2 million people may be affected by the disease by 2050.
This year, World Alzheimer’s Day is on September 21, 2022. As part of the theme, “Know dementia, Know Alzheimer’s”, we invite you to take another look at the impact of this neurodegenerative disease on the different types of memory: not all types of memory are affected in the same way by the disease, and some memories are relatively well preserved.
You may also be interested in other projects we have carried out on this theme for the “Observatoire des mémoires du Groupe B2V”:
Further information about the types of memory affected in Alzheimer’s disease can be found at:
For information on the disease, its impact on daily life, and the latest World Alzheimer Report, you can download the open-access resources available from websites of Alzheimer’s Disease International and the Vaincre Alzheimer Foundation:
Information about ongoing research projects and recent research advances can be found on the websites of Alzheimer Europe and the Fondation Recherche Alzheimer:
Synergy Pharm keeps you informed about medication safety, the theme chosen by the World Health Organization (WHO) for the 2022 edition of World Patient Safety Day.
Several regulatory documents are required to ensure the safety of a drug before it is made available on the market.
Ensuring the safe use of medication is essential for reducing patient harm. Especially since the COVID-19 pandemic has significantly exacerbated the risk of medication errors and associated medication-related harm. There are several interventions that can help to limit the frequency and impact of medication errors.
We can also support you in writing the scientific article relating to your clinical investigation.
Recent examples of articles about IVDMDs written by our team include:
Do not hesitate to contact us to discuss your projects!
April 18 is European Patients’ Rights Day (EPRD).
More specifically, this charter proclaims:
The European Clinical Trials Regulation (Regulation (EU) No 536/2014) also aims to guarantee the rights of patients, and all of the medical writers at Synergy Pharm/Santé Active Edition are committed to ensuring that information relating to compliance with ethical standards and good clinical practice is clearly stated in publications reporting the results of clinical trials.
On the occasion of the national “Week Against Cancer” campaign in France, it is important to highlight research efforts aimed at reducing the side effects associated with cancer treatments.
Indeed, while the range of treatments available – used alone or in combination – are effective against cancer, they can have many side effects, particularly on the skin. Xerosis is one of the most frequent side effects of cancer therapy and requires appropriate management to help maintain patient quality of life and prevent potential interruptions to cancer treatment.
A recent multicenter, real-world, phase IV study demonstrated the benefits of using an emollient containing a postbiotic in the management of 319 patients with xerosis associated with a range of cancer treatments (chemotherapy, targeted therapy, radiotherapy, hormonotherapy and immunotherapy).
A previous multicentre, real-world, phase IV study had already demonstrated the effectiveness of this emollient for the management of xerosis in 5,910 patients with a range of skin conditions (atopic dermatitis, senile xerosis, ichthyosis, psoriasis, prurigo nodularis of Hyde etc.) and underlying systemic conditions (diabetes mellitus, thyroid disease, renal insufficiency, etc.).
These two articles, published in Dermatology and Therapy and written by our medical writing team, can be found here:
*Learning, Brain and Artificial Intelligence, Brain and New Technologies, Brain and Society, Brain and Sport, Sleep, The 5 senses, Emotions, Memory, The Sick Brain.
By definition, a rare disease has a prevalence of 1/2,000. But rare diseases are numerous and would affect more than 3 million people in France, more than 300 million in the world!
Most of these diseases have no treatment. Nevertheless, many actors are mobilized in the fight against rare diseases to improve the diagnosis, care and follow-up of the patients concerned; research in this area also allows significant medical advances.
In 2021, we again had the opportunity to put our medical writing skills at the service of several rare diseases, including craniofacial microsomia, cystic fibrosis, and inherited epidermolysis bullosa.Read more